1. H. Bekemeier, R. Hirschelmann, A. Langner, A. J. Giessler, E. Krause, T. Funke, F. Haensel, K. Schmidt, S. Zarnack, H. H. Schumann and H. Ulbricht,Pharmacology of the lipoxygenase inhibitors oxphaman, 1-(2,5-dihydroxybenzylidene)amino-adamantan, and oxphalin, 1-(3,4-dihydroxybenzylidene)-2,4,6-trimethylalanin. Die Pharmazie44, 550–554 (1989).
2. H. Ulbricht, H. Bekemeier, R. Hirschelmann, R. Grupe, B. Böhme and W. Pietzsch,Structure and action of some new phenolic lipoxygenase inhibitors against different lipoxygenases in models of the inflammation, allergy and circulation. 6. Symposium “Potentielle Arzneistoffe”, Neubrandenburg, GDR, 24.–26. 3. 1987.
3. R. Grupe, T. Ziska, B. Böhme und E. Göres,Lipoxygenase-hemmstoffe und Mastzelldegranulation. Biomed. Biochim. Acta47, 955–963 (1988).
4. R. Grupe,Influence of cyclooxygenase- (COX-) and lipoxygenase-(LOX) inhibition on the degranulation of activated peritoneal rat mast cells (pRMC) in vitro. 12th European Workshop on inflammation, Halle (Saale), GDR, 30–31 May 1990, Agents and Actions32, 79–81 (1991).
5. W. Pietzsch, K.-H. Schwabe, K. Melchior and R. Grupe,Lipoxygenase-inhibitory azomethines and benzoylhydrazones. II. Effects of phenyl-substituted azomethines on the antigen-induced contractions of guinea pig lung parenchymal strips and jejunum segments. 12th European Workshop on inflammation, Halle (Saale), GDR, 30–31 May 1990, Agents and Actions32, 142–143 (1991).